NASDAQ:DBVT - Nasdaq - US23306J2006 - ADR - Currency: USD
4.395
+0.13 (+3.17%)
The current stock price of DBVT is 4.395 USD. In the past month the price decreased by -0.11%. In the past year, price decreased by -47.62%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 19.97 | 357.10B | ||
AMGN | AMGEN INC | 15.29 | 162.72B | ||
GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
NTRA | NATERA INC | N/A | 21.43B | ||
BIIB | BIOGEN INC | 8.54 | 20.49B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The company is headquartered in Chatillon, Auvergne-Rhone-Alpes and currently employs 106 full-time employees. The company went IPO on 2012-03-29. The firm's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. The company dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The firm's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The firm operates one subsidiary DBV Technologies Inc. in the United States.
DBV TECHNOLOGIES SA-SPON ADR
Batiment IRO, 107 Av. de la Republique
Chatillon AUVERGNE-RHONE-ALPES 92120 FR
CEO: Daniel Tasse
Employees: 106
Company Website: https://www.dbv-technologies.com/
Investor Relations: https://dbv-technologies.com/investor-overview/
Phone: 33155427878
The current stock price of DBVT is 4.395 USD. The price increased by 3.17% in the last trading session.
The exchange symbol of DBV TECHNOLOGIES SA-SPON ADR is DBVT and it is listed on the Nasdaq exchange.
DBVT stock is listed on the Nasdaq exchange.
7 analysts have analysed DBVT and the average price target is 10.36 USD. This implies a price increase of 135.67% is expected in the next year compared to the current price of 4.395. Check the DBV TECHNOLOGIES SA-SPON ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.
DBV TECHNOLOGIES SA-SPON ADR (DBVT) has a market capitalization of 90.17M USD. This makes DBVT a Micro Cap stock.
DBV TECHNOLOGIES SA-SPON ADR (DBVT) currently has 106 employees.
DBV TECHNOLOGIES SA-SPON ADR (DBVT) has a support level at 4.34 and a resistance level at 4.46. Check the full technical report for a detailed analysis of DBVT support and resistance levels.
The Revenue of DBV TECHNOLOGIES SA-SPON ADR (DBVT) is expected to decline by -55.09% in the next year. Check the estimates tab for more information on the DBVT EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
DBVT does not pay a dividend.
DBV TECHNOLOGIES SA-SPON ADR (DBVT) will report earnings on 2025-03-06, after the market close.
DBV TECHNOLOGIES SA-SPON ADR (DBVT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.22).
The outstanding short interest for DBV TECHNOLOGIES SA-SPON ADR (DBVT) is 2.07% of its float. Check the ownership tab for more information on the DBVT short interest.
ChartMill assigns a technical rating of 6 / 10 to DBVT. When comparing the yearly performance of all stocks, DBVT is one of the better performing stocks in the market, outperforming 85.86% of all stocks.
ChartMill assigns a fundamental rating of 3 / 10 to DBVT. DBVT may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months DBVT reported a non-GAAP Earnings per Share(EPS) of -4.22. The EPS increased by 19.64% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -63.7% | ||
ROE | -91.83% | ||
Debt/Equity | 0.09 |
ChartMill assigns a Buy % Consensus number of 83% to DBVT. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of -36.93% and a revenue growth -55.09% for DBVT